S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Eupraxia Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:EPRXF)

C$4.23
0.00 (0.00%)
(As of 12/5/2023 ET)
Compare
Today's Range
C$4.23
C$4.23
50-Day Range
C$3.96
C$5.52
52-Week Range
C$2.69
C$6.78
Volume
N/A
Average Volume
2,316 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$18.00

EPRXF stock logo

About Eupraxia Pharmaceuticals Stock (OTCMKTS:EPRXF)

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

EPRXF Stock Price History

EPRXF Stock News Headlines

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
Mirum Pharmaceuticals earnings preview: what Wall Street is expecting
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Eupraxia Pharmaceuticals Announces Change of Auditor
See More Headlines
Receive EPRXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:EPRXF
CIK
N/A
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$18.00
High Stock Price Target
C$18.00
Low Stock Price Target
C$18.00
Potential Upside/Downside
+326.0%
Consensus Rating
Strong Buy
Rating Score (0-4)
4.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. James A. Helliwell FRCPC (Age 49)
    M.D., CEO & Director
    Comp: $457.19k
  • Mr. Bruce G. Cousins C.A. (Age 62)
    CPA, President & CFO
    Comp: $307.23k
  • Dr. Amanda Malone Ph.D. (Age 42)
    Chief Scientific Officer
    Comp: $338.8k
  • Mr. Paul Anthony Brennan B.Sc.
    M.Sc., Chief Business Officer
  • Dr. Mark M. Kowalski M.D. (Age 68)
    Ph.D., Chief Medical Officer














EPRXF Stock Analysis - Frequently Asked Questions

Should I buy or sell Eupraxia Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eupraxia Pharmaceuticals in the last year. There are currently 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" EPRXF shares.
View EPRXF analyst ratings
or view top-rated stocks.

What is Eupraxia Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued 1-year price targets for Eupraxia Pharmaceuticals' shares. Their EPRXF share price targets range from C$18.00 to C$18.00. On average, they expect the company's share price to reach C$18.00 in the next year. This suggests a possible upside of 326.0% from the stock's current price.
View analysts price targets for EPRXF
or view top-rated stocks among Wall Street analysts.

How have EPRXF shares performed in 2023?

Eupraxia Pharmaceuticals' stock was trading at C$2.69 at the beginning of 2023. Since then, EPRXF shares have increased by 57.1% and is now trading at C$4.23.
View the best growth stocks for 2023 here
.

Are investors shorting Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 5,800 shares, an increase of 13.7% from the October 15th total of 5,100 shares. Based on an average daily volume of 1,400 shares, the short-interest ratio is presently 4.1 days.
View Eupraxia Pharmaceuticals' Short Interest
.

How do I buy shares of Eupraxia Pharmaceuticals?

Shares of EPRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:EPRXF) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -